Atrion (NASDAQ:ATRI) Lifted to Sell at BidaskClub

BidaskClub upgraded shares of Atrion (NASDAQ:ATRI) from a strong sell rating to a sell rating in a report released on Saturday morning, BidAskClub reports.

Shares of Atrion stock opened at $653.00 on Friday. The firm’s 50 day moving average price is $638.23 and its 200-day moving average price is $649.27. Atrion has a 52-week low of $579.00 and a 52-week high of $846.15. The company has a market cap of $1.19 billion, a P/E ratio of 34.46 and a beta of 0.11.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $4.68 earnings per share (EPS) for the quarter. Atrion had a net margin of 22.70% and a return on equity of 14.98%. The firm had revenue of $37.97 million for the quarter.

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Tuesday, September 15th were paid a $1.75 dividend. The ex-dividend date was Monday, September 14th. This is a boost from Atrion’s previous quarterly dividend of $1.55. This represents a $7.00 dividend on an annualized basis and a yield of 1.07%.

A number of hedge funds have recently added to or reduced their stakes in the stock. Nachman Norwood & Parrott Inc acquired a new stake in Atrion in the 3rd quarter worth approximately $50,000. Boston Trust Walden Corp boosted its stake in Atrion by 4.5% in the 3rd quarter. Boston Trust Walden Corp now owns 26,431 shares of the medical instruments supplier’s stock worth $16,545,000 after purchasing an additional 1,131 shares in the last quarter. Neuberger Berman Group LLC boosted its stake in Atrion by 4.3% in the 2nd quarter. Neuberger Berman Group LLC now owns 172,423 shares of the medical instruments supplier’s stock worth $109,835,000 after purchasing an additional 7,119 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Atrion by 2.7% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 9,129 shares of the medical instruments supplier’s stock worth $5,816,000 after purchasing an additional 236 shares in the last quarter. Finally, Cubist Systematic Strategies LLC boosted its stake in Atrion by 198.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 952 shares of the medical instruments supplier’s stock worth $606,000 after purchasing an additional 633 shares in the last quarter. Institutional investors own 65.70% of the company’s stock.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

See Also: What is a Reverse Stock Split?

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.